CN104784127A - Acyclovir tablet composition - Google Patents
Acyclovir tablet composition Download PDFInfo
- Publication number
- CN104784127A CN104784127A CN201410020487.XA CN201410020487A CN104784127A CN 104784127 A CN104784127 A CN 104784127A CN 201410020487 A CN201410020487 A CN 201410020487A CN 104784127 A CN104784127 A CN 104784127A
- Authority
- CN
- China
- Prior art keywords
- acyclovir
- tablet
- starch
- cellulose
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to an acyclovir tablet composition, which comprises acyclovir, a binder, a disintegrant, a lubricant and a filler, wherein the binder is selected from ethanol, a starch slurry, sodium carboxymethyl cellulose, hydroxypropyl cellulose and a polyvinylpyrrolidone ethanol solution, the disintegrant is selected from dry starch, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, and cross-linked sodium carboxymethyl cellulose, the lubricant is selected from magnesium stearate, silica gel micro-powder, and talc powder, and the filler is selected from lactose, compressible dry starch, and microcrystalline cellulose. According to the present invention, the suitable prescription is preferably selected, the formula is accurate, the reasonable auxiliary material ratio is designed, and the disintegration time limit of the acyclovir is effectively reduced; and the disintegration time limit of the acyclovir is less than 12 min.
Description
Technical field
The present invention relates to the configuration of a kind of medicine containing organic effective component product, particularly a kind of Acyclovir Tablet compositions.
Background technology
The purine nucleoside analogs that acyclovir (Aciclovir) is a kind of synthesis.Be mainly used in the various infection caused by herpes simplex virus, can be used for onset or recurring skin, mucosa, the HSV that external genitalia infects and immunodeficiency person occurs infects.For the choice drug for the treatment of HSV encephalitis, minimizing sickness rate and reduction mortality rate are all better than vidarabine.Also can be used for herpes zoster, Epstein-Barr virus, and the infection such as the concurrent chickenpox of immunodeficiency person.Local is only for skin, and the skin of acyclovir absorbs less.Acyclovir researched and developed successfully in 1981 by Glaxo Wellcome company of Britain, belongs to uncleosides as antiviral agents.This medicine is first in Britain's listing, and to the various herpesviruss of skin and ophthalmology, particularly single bleb I, II type virus, the diseases such as the chronic hepatitis of cytomegalovirus and the hepatitis B antigen positive are effective.As the milestone of second filial generation antiviral drugs, having that antiviral spectrum is comparatively wide, effect is strong, selectivity is high, safety, oral hygiene availability comparatively high, is the choice drug being used for the treatment of herpes simplex infections at present clinically.
Tablet uses on basis at pill and grows up, and its wound is used for 19th-century forties, and to 19 end of the centurys along with the appearance of compression machinery with update, the production of tablet and application obtain and develop rapidly.In recent ten years, also there is larger development tablet manufacturing technology and plant equipment aspect, as boiling granulating, direct compression of full-powder, half film coating, new adjuvant, new technology and production interlockization etc.The prescription of tablet medicine comprises: appearance character, tablet weight variation, hardness and friability, disintegration, dissolution or release, uniformity of dosage units etc., and wherein disintegration is most important for the treatment of disease.Select adhesive improper in prior art, supplementary material water content is improper, and lubricant uses too much these all can cause the prolongation of disintegration.
Summary of the invention
The object of the invention is to solve above-mentioned deficiency, the Acyclovir Tablet compositions that a kind of prescription is reasonable, disintegration is short is provided.
The technical scheme realizing the object of the invention is: a kind of Acyclovir Tablet compositions, and by acyclovir, binding agent, disintegrating agent and lubricant, filler forms.
Above-mentioned Acyclovir Tablet compositions, described binding agent be in ethanol, starch slurry, sodium carboxymethyl cellulose, hydroxypropyl cellulose and polyvinylpyrrolidone alcoholic solution one or more; Described disintegrating agent be in dried starch, carboxymethyl starch sodium, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose one or more; Described lubricant be in magnesium stearate, micropowder silica gel, Pulvis Talci one or more; Described filler be in lactose, compressibility dried starch, microcrystalline Cellulose one or more.
Above-mentioned Acyclovir Tablet compositions, described binding agent is hydroxypropyl cellulose and 5% polyvinylpyrrolidone alcoholic solution; Described disintegrating agent is carboxymethyl starch sodium; Described lubricant is magnesium stearate and micropowder silica gel; Described filler is microcrystalline Cellulose.
Above-mentioned Acyclovir Tablet compositions, the mass percent of each component is:
Above-mentioned Acyclovir Tablet compositions, the mass percent of preferred each component is:
Above-mentioned Acyclovir Tablet compositions, more preferably the mass percent of each component is:
Acyclovir, Chinese another name: acycloguanosine; Acycloguanosine; ACG; ACC; ACC; Chemistry 9-(2-hydroxyl ethoxymethyl) guanine by name.
Beneficial effect of the present invention: (1) the present invention optimizes suitable prescription, formula is accurate, and designs the proportioning of rational adjuvant, effectively reduces the disintegration of acyclovir; (2) disintegration of acyclovir of the present invention is for being less than 12 minutes.
Detailed description of the invention
(embodiment 1) takes each main ingredient according to following proportioning:
Adopt the equipment such as three-dimensional mixer and tablet machine according to the operation of granulation, drying, mixing, tabletting, above-mentioned each component is prepared into Acyclovir Tablet.Adopting disintegration of tablet time limit analyzer to measure disintegration is 11.5 minutes.(embodiment 2) takes each main ingredient according to following proportioning:
Adopt the equipment such as three-dimensional mixer and tablet machine according to the operation of granulation, drying, mixing, tabletting, above-mentioned each component is prepared into Acyclovir Tablet.Adopting disintegration of tablet time limit analyzer to measure disintegration is 11.2 minutes.(embodiment 3) takes each main ingredient according to following proportioning:
Adopt the equipment such as three-dimensional mixer and tablet machine according to the operation of granulation, drying, mixing, tabletting, above-mentioned each component is prepared into Acyclovir Tablet.Adopting disintegration of tablet time limit analyzer to measure disintegration is 11.4 minutes.(embodiment 4) takes each main ingredient according to following proportioning:
Adopt the equipment such as three-dimensional mixer and tablet machine according to the operation of granulation, drying, mixing, tabletting, above-mentioned each component is prepared into Acyclovir Tablet.Adopting disintegration of tablet time limit analyzer to measure disintegration is 10.8 minutes.(embodiment 5) takes each main ingredient according to following proportioning:
Adopt the equipment such as three-dimensional mixer and tablet machine according to the operation of granulation, drying, mixing, tabletting, above-mentioned each component is prepared into Acyclovir Tablet.Adopting disintegration of tablet time limit analyzer to measure disintegration is 10.9 minutes.(embodiment 6) takes each main ingredient according to following proportioning:
Adopt the equipment such as three-dimensional mixer and tablet machine according to the operation of granulation, drying, mixing, tabletting, above-mentioned each component is prepared into Acyclovir Tablet.Adopting disintegration of tablet time limit analyzer to measure disintegration is 10.8 minutes.(embodiment 7) takes each main ingredient according to following proportioning:
Adopt the equipment such as three-dimensional mixer and tablet machine according to the operation of granulation, drying, mixing, tabletting, above-mentioned each component is prepared into Acyclovir Tablet.Adopting disintegration of tablet time limit analyzer to measure disintegration is 11.0 minutes.(embodiment 8) takes each main ingredient according to following proportioning:
Adopt the equipment such as three-dimensional mixer and tablet machine according to the operation of granulation, drying, mixing, tabletting, above-mentioned each component is prepared into Acyclovir Tablet.Adopting disintegration of tablet time limit analyzer to measure disintegration is 11.1 minutes.
Above-described specific embodiment; object of the present invention, technical scheme and beneficial effect are further described; be understood that; the foregoing is only specific embodiments of the invention; be not limited to the present invention; within the spirit and principles in the present invention all, any amendment made, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (6)
1. an Acyclovir Tablet compositions, is characterized in that: by acyclovir, binding agent, disintegrating agent, lubricant and filler composition.
2. Acyclovir Tablet compositions according to claim 1, is characterized in that: described binding agent be in ethanol, starch slurry, sodium carboxymethyl cellulose, hydroxypropyl cellulose and polyvinylpyrrolidone alcoholic solution one or more; Described disintegrating agent be in dried starch, carboxymethyl starch sodium, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose one or more; Described lubricant be in magnesium stearate, micropowder silica gel, Pulvis Talci one or more; Described filler be in lactose, compressibility dried starch, microcrystalline Cellulose one or more.
3. Acyclovir Tablet compositions according to claim 1, is characterized in that: described binding agent is hydroxypropyl cellulose and 5% polyvinylpyrrolidone alcoholic solution; Described disintegrating agent is carboxymethyl starch sodium; Described lubricant is magnesium stearate and micropowder silica gel; Described filler is microcrystalline Cellulose.
4. Acyclovir Tablet compositions according to claim 3, is characterized in that: the mass percent of each component is:
5. Acyclovir Tablet compositions according to claim 4, is characterized in that: the mass percent of each component is:
6. Acyclovir Tablet compositions according to claim 5, is characterized in that: the mass percent of each component is:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410020487.XA CN104784127A (en) | 2014-01-16 | 2014-01-16 | Acyclovir tablet composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410020487.XA CN104784127A (en) | 2014-01-16 | 2014-01-16 | Acyclovir tablet composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104784127A true CN104784127A (en) | 2015-07-22 |
Family
ID=53549634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410020487.XA Pending CN104784127A (en) | 2014-01-16 | 2014-01-16 | Acyclovir tablet composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104784127A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113274356A (en) * | 2021-05-25 | 2021-08-20 | 丽珠集团丽珠制药厂 | Valaciclovir hydrochloride granules and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1927342A (en) * | 2006-09-05 | 2007-03-14 | 江西本草天工科技有限责任公司 | Heat clearing and detoxicating dispersant tablet and method for making same |
| CN101361719A (en) * | 2008-08-29 | 2009-02-11 | 南昌弘益科技有限公司 | Bromhexine hydrochloric acid orally disintegrating tablet production method |
| CN101804037A (en) * | 2009-02-13 | 2010-08-18 | 北京以岭生物工程有限公司 | Acyclovir dispersible tablet and preparation method thereof |
-
2014
- 2014-01-16 CN CN201410020487.XA patent/CN104784127A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1927342A (en) * | 2006-09-05 | 2007-03-14 | 江西本草天工科技有限责任公司 | Heat clearing and detoxicating dispersant tablet and method for making same |
| CN101361719A (en) * | 2008-08-29 | 2009-02-11 | 南昌弘益科技有限公司 | Bromhexine hydrochloric acid orally disintegrating tablet production method |
| CN101804037A (en) * | 2009-02-13 | 2010-08-18 | 北京以岭生物工程有限公司 | Acyclovir dispersible tablet and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113274356A (en) * | 2021-05-25 | 2021-08-20 | 丽珠集团丽珠制药厂 | Valaciclovir hydrochloride granules and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI745349B (en) | A pharmaceutical composition comprising jak kinase inhibitor or its medicinal salt thereof | |
| NZ729172A (en) | Combination formulation of two antiviral compounds | |
| ES2465478T3 (en) | Pharmaceutical compositions comprising brivaracetam | |
| WO2014143935A4 (en) | Rapidly dispersible dosage form of oxcarbazepine | |
| SI3079671T1 (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
| JP2016540021A5 (en) | ||
| JP2017105815A (en) | Stable pharmaceutical composition | |
| RU2011134847A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING A PHOSPHATE BINDING POLYMER | |
| RU2013106172A (en) | COMPOSITION FOR REDUCING FATIGUE, COMPOSITION AND THEIR APPLICATION | |
| RU2010101797A (en) | PHARMACEUTICAL SOLID PRODUCT CONTAINING BENZAZEPINE AND METHOD FOR PRODUCING IT | |
| CN106860414B (en) | anti-HIV compound preparation and preparation method and application thereof | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| CN103340869A (en) | Composition for impotence and premature ejaculation | |
| JP6009967B2 (en) | Solid preparation | |
| CA2531853A1 (en) | Pharmaceutical formulation comprising levothyroxine sodium | |
| CN104784127A (en) | Acyclovir tablet composition | |
| JP2011516544A5 (en) | ||
| RU2015129714A (en) | COMPOSITION IN THE FORM OF TABLETS CONTAINING ZINACALCET HYDROCHLORIDE | |
| RU2014143529A (en) | Crystalline forms of (S) -4-amino-N- (1- (4-chlorophenyl) -3-hydroxypropyl) -1- (7H-pyrrolo [2, 3-d] pyrimidin-4-yl) piperidin-4-carboxamide | |
| JP2017520619A5 (en) | ||
| NZ584968A (en) | Novel antiretroviral combination comprising ritonavir and atazanavir | |
| CN106860464A (en) | Pharmaceutical composition and application for combination antiviral therapy | |
| JP6073231B2 (en) | Stable pharmaceutical composition | |
| CN104784126B (en) | A kind of preparation method of Acyclovir Tablet composition | |
| CN101797253B (en) | Bergenin and cetirizine dihydrochloride compound oral administration preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150722 |